Form D · Pharmaceuticals
pecan biotherapeutics, Inc
Dallas, TX · CIK 0001451233
Offering snapshot reported Oct 30, 2009 · SEC filing
- Reported sold
- $250K Offering amount: $250K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $250K Reported outside-investor minimum
- First sale
- Aug 28, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 30, 2009 | Initial | $250,000 | No comparison | 1 | SEC filing |
| Nov 21, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-124899
Source: Form D, filed Oct 30, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Banigan | Director |
| Joel Fineberg | Director |
| Steve Malouf | Director |
| Craig Rosenfeld | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3811 Turtle Creek Blvd. Suite 1900
Dallas, TX, 75219
Dallas, TX, 75219